NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Gap Up to $0.62

Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) gapped up before the market opened on Tuesday . The stock had previously closed at $0.51, but opened at $0.62. NovaBay Pharmaceuticals shares last traded at $0.62, with a volume of 14,184 shares traded.

A number of equities research analysts have recently issued reports on the company. LADENBURG THALM/SH SH initiated coverage on NovaBay Pharmaceuticals in a report on Wednesday, September 18th. They set a “buy” rating and a $1.10 price objective for the company. Zacks Investment Research upgraded NovaBay Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Wednesday, November 20th.

The firm has a 50-day simple moving average of $0.68 and a two-hundred day simple moving average of $1.02.

A hedge fund recently raised its stake in NovaBay Pharmaceuticals stock. Renaissance Technologies LLC grew its holdings in shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) by 1,283.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 412,469 shares of the biopharmaceutical company’s stock after purchasing an additional 382,645 shares during the period. Renaissance Technologies LLC owned about 1.96% of NovaBay Pharmaceuticals worth $697,000 at the end of the most recent quarter.

NovaBay Pharmaceuticals Company Profile (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

Featured Article: What is a Fiduciary?

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit